Pediatrix Medical Group appoints former children’s hospital CEO to board

FORT LAUDERDALE - Pediatrix Medical Group, Inc. (NYSE:MD), a healthcare company with a market capitalization of $1.21 billion and an overall GREAT financial health score according to InvestingPro, has appointed Dr. Kurt D. Newman to its board of directors effective July 1, according to a company press release.

Dr. Newman, the former President and Chief Executive Officer of Children’s National Hospital in Washington, D.C., joins Pediatrix as an independent director. He served 12 years as CEO at Children’s National after spending over 25 years there as a pediatric surgeon. His appointment comes at a crucial time as analysts have revised earnings expectations upward for the upcoming period, with the company scheduled to report its next earnings on July 31.

Mark S. Ordan, Chair of the Board and Chief Executive Officer of Pediatrix, said the company is "thrilled" to welcome Dr. Newman, noting his "deep understanding of patient needs, clinical practices and the evolving healthcare landscape."

Dr. Newman is recognized for his leadership in pediatric healthcare. He was named CEO of the Year by the Washington Business Journal in 2021 and inducted into the Washington Business Hall of Fame in 2023. He is also the author of "Healing Children: a Surgeon’s Stories from the Frontiers of Pediatric Medicine."

"The physician voice is central to patient-centered decision making," Dr. Newman said in the statement. "I look forward to contributing my experience to strengthen collaboration between physicians, other clinicians, executive leadership and the board."

Dr. Newman currently serves on the boards of Children’s Miracle Network Hospitals, Corus International, Fight for Children, and the Potomac Conservancy.

Pediatrix Medical Group provides physician services with approximately 4,400 affiliated physicians and clinicians specializing in obstetrics, maternal-fetal medicine, neonatology, and various pediatric subspecialties. The company’s stock has shown remarkable strength, delivering a 101.83% return over the past year, and according to InvestingPro analysis, the stock appears undervalued at current levels. Discover more insights and 5 additional ProTips about Pediatrix Medical Group with an InvestingPro subscription, including detailed analysis in the comprehensive Pro Research Report.

In other recent news, Pediatrix Medical Group Inc. reported financial results for the first quarter of 2025 that exceeded expectations. The company achieved earnings per share (EPS) of $0.33, surpassing the forecasted $0.24. Revenue also outperformed projections, reaching $458.36 million compared to the anticipated $451.44 million. Pediatrix has raised its full-year adjusted EBITDA outlook to a range of $220-$240 million, reflecting confidence in its operational strategies. The company maintains a strong cash position with $99 million and a net leverage of 2.2 times. Additionally, Pediatrix is actively engaging in hospital partnerships and has contracted to acquire several NICU, MFM, and OB Hospitalist operations. The company continues to focus on recruiting and retaining clinical talent as part of its strategic priorities for 2025. UBS analysts inquired about the company’s guidance, with CEO Mark Carden noting a conservative stance due to ongoing economic uncertainties.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.